Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. - Wikidata - awgldk - TriplyDB

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

http://www.wikidata.org/entity/Q34333955

about

Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics Niacin, an old drug with a new twist Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins GPR109A and vascular inflammation The therapeutic role of niacin in dyslipidemia management Niacin stimulates adiponectin secretion through the GPR109A receptor Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease Future of GPR109A agonists in the treatment of dyslipidaemia.Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease.Extended-release niacin acutely suppresses postprandial triglyceridemia.Niacin: another look at an underutilized lipid-lowering medication.Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis.A unified framework for association analysis with multiple related phenotypes.Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.Overexpression of full-length cholesteryl ester transfer protein in SW872 cells reduces lipid accumulation Effects of niacin on atherosclerosis and vascular function.Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug.Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2 Defective triglyceride biosynthesis in CETP-deficient SW872 cells.Niacin in cardiovascular disease: recent preclinical and clinical developments Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.Expression of Soluble Forms of Yeast Diacylglycerol Acyltransferase 2 That Integrate a Broad Range of Saturated Fatty Acids in Triacylglycerols.Nicotinic acid: an old drug with a promising future Nicotinic acid supplementation in diet favored intramuscular fat deposition and lipid metabolism in finishing steers.Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention.Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.The mechanism and mitigation of niacin-induced flushing.Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: a qualitative review.A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.Niacin, an old drug with new perspectives for the management of dyslipidaemia.Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.Atherosclerosis regression and high-density lipoproteins.New evidence for nicotinic acid treatment to reduce atherosclerosis.Emerging options in the treatment of dyslipidemias: a bright future?The facts behind niacin.

P2860

Q26765137-E85F1128-CF80-4E72-93E8-9A19CDA4C06B Q27002774-291DAE1E-1E3B-4B06-9817-5D3DAE62B290 Q28200554-CF6CF01E-A011-4904-B937-7C8B012C72E0 Q28287747-3B2D5A26-6776-4315-B1E6-28EA0FEACE46 Q28304559-47ECF04F-9C43-42E7-8CE7-C5BC4F3A297D Q28575089-B9E1E55C-D5BA-402E-9519-37DD6D4BA9C0 Q33776194-A2059E55-B766-462E-94E3-E5B6969F9883 Q33984899-6D746AF5-7CC6-473F-8BFE-F0B30CDD1ADE Q34171831-BA49F76F-7517-4EB0-A20C-BC434EB48659 Q34187979-A6C38060-AED0-431A-B237-DF19E1C3E597 Q34223452-934C903E-FAD0-4E6E-945F-8749D1710569 Q34255686-217F3DD4-325D-435E-B902-7EA09BFECE98 Q34624990-AFAA67EF-7772-4162-9691-263E7B563B0F Q34817393-AAAB901B-38FF-4CDB-A39C-AD0A62AC0637 Q34825206-6C936462-54E4-487D-B530-A5B6D55453AA Q34931247-DBD2D53A-37EB-4136-B0F6-02A36C9F53C1 Q35120890-C254DD02-4AC5-46AB-9395-BBACCEDDE593 Q35132366-B4D8F70C-4543-43B2-B212-A8F49AEAFE68 Q35230819-8C0E0158-3387-4162-A1C9-B1C84470E9DC Q35432791-86388928-13EB-47BB-A0FA-04C787C26797 Q35839709-38FD2146-BDE8-46DE-B68E-619C9752B472 Q35958448-0EE9241F-EEF2-41EF-ABF8-85259CE4F511 Q35994348-18050E0D-8380-4382-B815-4588A35C9D25 Q36084389-A71A2088-A521-405F-AE6B-15A12CFDD887 Q36152978-5D6C128F-53AA-4E87-A551-9CC341D0CE55 Q36174116-1563082D-417D-4D50-B32F-A63DD4CC9F9F Q36497035-7737ECC8-EFF0-4913-BE66-7B0BEC147374 Q37107041-63C3A520-29F1-4CA1-B44C-D6CB0989AD26 Q37329136-397E7A5F-A855-4817-BC02-04488F539E05 Q37367896-8D7D2DC9-063C-40C6-B920-7ACD626AC4A9 Q37386911-74E3B52A-6745-47D3-B4AF-C385F5436FDD Q37582460-B25AEAF3-85C9-4A95-B966-01AC63969AAA Q37667487-5D6E0EBF-BBA3-4910-8E06-4395ED6AFB13 Q37689135-1BCF08C5-7EFD-465C-A583-A0949DCDCE7A Q37725868-EEB4CDAB-0186-4A33-A889-A95F82E2AA15 Q37772510-F348DD20-1EFD-42A0-8BB9-C2C30F324930 Q37786650-FECB83D8-68D9-42CE-BD5C-B77E28D3A635 Q37799365-FE30507F-5746-4163-8716-5B1ECE1F0592 Q37842462-51A0ABA5-3562-46F2-9F2A-329A721D17F5 Q37926768-D9548653-A649-49B8-8356-225EE472FBD4

P2860

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

http://www.wikidata.org/entity/Q34333955

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

@ast

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

@en

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

@nl

type

label

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

@ast

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

@en

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

@nl

prefLabel

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

@ast

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

@en

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

@nl

P1433

Q34333955-89311F42-2D11-42E0-ADE9-29A75579B1DA

P1476

Q34333955-FCF25FA5-4DCB-422D-8873-CAB1C6387725

P2093

Q34333955-0EF69C21-A191-4323-A7A3-554B46B1D8F1

Q34333955-37740631-33C7-459C-A701-B5D970D88364

Q34333955-5A77A570-3CC0-433B-8A08-36419D60B974

Q34333955-76836A9E-EFC2-4B12-9D4E-F2DD873D1965

Q34333955-8A5035DC-EF53-4AC3-A596-4BBA5E7E1054

Q34333955-F6F8CCD3-6F53-40F5-A0B5-5E967855E44C

P2860

Q34333955-07D46BD6-3209-4FA8-9B8C-858D9342044A

Q34333955-2409C22A-7340-4121-B64C-53D1C466E5EF

Q34333955-32905BD0-3FB7-4DB7-8CF1-F12F4E3BE5D0

Q34333955-3684208E-1187-48B8-9FA9-13D00A382D0D

Q34333955-3C3733D0-0E53-413D-A9E8-983C86E2B95E

Q34333955-422A06C7-4307-45E6-AEEA-AF1CAAA95EBE

Q34333955-4CAFA4F7-599C-4C80-8231-DF0058D5D59A

Q34333955-4F2EEBE0-A8AC-4208-BC61-8D58BDCE61E6

Q34333955-536857B9-546A-4927-A5CD-BBEA7881562C

Q34333955-694FCE85-9E49-4236-99E6-E30B3EB3AED4

P304

Q34333955-95160153-A407-47FB-9300-14D6B6B19F14

P31

Q34333955-6778F768-80A3-4954-97FA-744B21DCBC67

P356

Q34333955-F7396723-CB20-44F7-B02F-580DFEF3183B

P433

Q34333955-EAF69F29-4F21-4A20-AE71-DE24121EAD02

P478

Q34333955-EFB3D000-CB77-4B88-85FF-4B51D5EFE730

P577

Q34333955-7A2A8C32-83C5-450A-B529-294FC24B8A7B

P698

Q34333955-162F794A-D4BC-449F-9F23-824621520D82

P356

JLR.M300403-JLR200

P1433

Journal of Lipid Research

P1476

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

@en

P2093

Daming Zhu

http://www.w3.org/2001/XMLSchema#string

Moti L Kashyap

http://www.w3.org/2001/XMLSchema#string

S Tavintharan

http://www.w3.org/2001/XMLSchema#string

Shobha H Ganji

http://www.w3.org/2001/XMLSchema#string

Vaijinath S Kamanna

http://www.w3.org/2001/XMLSchema#string

Yiding Xing

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes

Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members

Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis

Molecular identification of high and low affinity receptors for nicotinic acid

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

2-Bromopalmitoyl-CoA and 2-bromopalmitate: promiscuous inhibitors of membrane-bound enzymes

Solubilization, partial purification and characterization of rat liver microsomal diacylglycerol acyltransferase

The benefits of niacin in atherosclerosis.

Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver.

Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat.

P304

1835-1845

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1194/JLR.M300403-JLR200

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2004-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15258194

http://www.w3.org/2001/XMLSchema#string